•
Sep 30, 2022
ANI Pharmaceuticals Q3 2022 Earnings Report
ANI Pharmaceuticals delivered record net revenues and made significant progress in its key business lines
Key Takeaways
ANI Pharmaceuticals reported record net revenues of $83.8 million, a 61% year-over-year increase. The company is maintaining its 2022 revenue guidance of $295 million to $315 million and adjusted non-GAAP EBITDA guidance of $54 million to $60 million.
ANI delivered record net revenues of $83.8 million, a 61% year-over-year growth and 13% quarter-on-quarter growth.
Non-GAAP EBITDA increased from $4.3 million in Q1 to $9.9 million in Q2 to $19.6 million in Q3 2022.
Cortrophin revenue grew to $12.6 million, up from $10.2 million in the second quarter.
Generic revenues grew by 51% over the prior year quarter.
ANI Pharmaceuticals
ANI Pharmaceuticals
Forward Guidance
ANI Pharmaceuticals is reiterating its full year 2022 guidance.
Positive Outlook
- Total Company Net Revenue between $295.0 million and $315.0 million, representing approximately 36% to 46% growth as compared to $216.1 million recognized in 2021
- Cortrophin specific net revenue guidance between $40.0 million to $45.0 million